Cargando…
2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
BACKGROUND: Cefepime is a fourth-generation cephalosporin antibiotic used for the treatment of neutropenic fever, pneumonia, and urinary tract infections. The safety of cefepime is now being questioned as it has recently been implicated as a possible cause for lesser known adverse effects, including...
Autores principales: | Groff, Lindsey, Teng, Chengwen, Encarnacion, Victor, Razzack, Huda, Obodozie-Ofoegbu, Obiageri, Frei, Christopher R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254527/ http://dx.doi.org/10.1093/ofid/ofy210.1828 |
Ejemplares similares
-
Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019) -
Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019) -
1881. Empiric Pseudomonal Monotherapy vs. Combination Therapy for Community-Onset Pneumonia in Older Adults
por: Obodozie-Ofoegbu, Obiageri, et al.
Publicado: (2018) -
2296. Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
por: Kennedy, Kaitlin E, et al.
Publicado: (2019) -
1977. Comparing Acute Kidney Injury Risk among Antibiotic Classes: A Study of the FDA Adverse Event Reporting System (FAERS)
por: Patek, Taylor M, et al.
Publicado: (2019)